Robin Kleiman, PhD

Chief Scientific Officer

• Myrobalan Therapeutics’ Chief Scientific Officer, bringing over 25 years of neuroscience drug discovery expertise across biotech, pharma, and academia
• Translated multiple novel target mechanisms into discovery and development candidates across a range of CNS disorders
• Previously served as VP of CNS Biology at Alkermes, directing preclinical efforts across exploratory, discovery, and early development stages, and strengthening discovery capabilities to anchor programs in human biology for a range of CNS indications.
• Founded the Translational Cellular Sciences group at Biogen, advancing iPSC-derived cell testing for therapeutic molecules and helped establish the Translational Neuroscience Center and Human Neuron Core at Boston Children’s Hospital
• Pfizer alumni – advanced multiple clinical candidates as a founding member of the CNS phosphodiesterase platform team that initiated three first-in-class clinical trials for novel CNS targets
• B.S. in Zoology from the University of Vermont, Ph.D. in Neuroscience from the University of Virginia, and postdoctoral training at UCSF
• Committed to delivering breakthrough treatments for severe CNS conditions, aiming to combine precision neuroscience and novel targets to develop transformative therapeutics at Myrobalan Therapeutics